Biotech 2050 Podcast cover image

98. Brain health disorders, Al Robichaud, Ph.D., CSO, Sage Therapeutics

Biotech 2050 Podcast

00:00

The Big Farm Industry - What Was That Experience Like for You?

i saw a shift way from sort of the innovative approach to drug discovery and a willingness to take on some risk associated with the orandy necessary to discover new medicines. The industry seemed to be changing a bit into companies that were looking at just incremental improvements, sort of evolutionary versus revolutionary. There are very little ways to measure things like scitoprenia, depression, anxiety, even cognition in animals, relative to how they would be in a human being. So that challenge has made it very difficult for companies to find success in the neuro science area. And i believe the neuro science drug success is somewhere on the order of 20 % of other areas like achology or cardovasc disease

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app